IDegLira (insulin degludec/liraglutide) / Novo Nordisk - LARVOL DELTA

The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study. (PubMed, Diabetes Res Clin Pract) - "IdegLira represents a viable option in deintensifying insulin therapy in an elderly population."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) for Treating 1499 Chinese Type 2 Diabetes Patients: A Real-World Prospective Observational Study (ChiCTR) - P4 | N=1499 | Completed | Sponsor: Beijing Hospital; Beijing Hospital

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Cost-Utility of IDegLira Versus Alternative Basal Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a Chinese Setting (ISPOR 2025) - "For T2DM patients uncontrolled on basal insulin, IDegLira was projected to be dominant and worthy of clinical promotion both compared with basal-bolus therapy and GLP-1RA added to basal insulin in the Chinese setting. Semaglutide has certain advantages in clinical practice, but its price is relatively high."

Clinical • HEOR • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

ROLE OF DIGITAL HEALTH IN THE MANAGEMENT OF IDEGLIRA THERAPY : THE IMPORTANCE OF EFFECTIVE TITRATION IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS (ATTD 2025) - "Background and Aims Digital Health represents a valid support tool in the educational paths of diabetic subjects.Methods In the present study, 81 subjects were enrolled (F 39.5% M 60.5%) started with IDegLira, metformin, SGLT2, 74% were naive to insulin treatment 25.9% from bolus reverse or BOT. They were classified as high users if they used the APP consistently(71.6 %),middle users(13.5%)if they used it only occasionally and No Users (14.8%). High users vs middle and no users did not have a difference in terms of average dose (26.4 ±13 vs 22.6 ±10.2 vs 23.1 ±10.2 p>0.05) but showed a significant difference in terms of improvement in compensation: Hba1c 1.6 ±0.5vs0.7 ±0.2 vs 0.6 ±0.2 p <0.05).The subjects were also asked: 85% responded very satisfied while the remaining 15% responded not satisfied so much so that they were then among the No- Users.Conclusions this study confirms that a supported titration with an APP DOSE CHECK..."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

GREATER SAFETY AND EFFICACY OF INSULIN DEGLUDEC/LIRAGLUTIDE COMPARED TO MDI IN THE TRANSITION FROM HOSPITAL TO OUTPATIENT MANAGEMENT IN T2D, EVALUATED BY CONTINUOUS GLUCOSE MONITORING (ATTD 2025) - "These findings were consistent regardless of baseline HbA1c. No severe hypoglycemic events occurred in either group.Conclusions The use of IDegLira was superior in terms of safety and efficacy for managing patients with poorly controlled T2DM during the transition from hospital to outpatient care."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024 (GlobeNewswire) - "Ozempic sales increased by 26% in both Danish kroner and at CER to DKK 120,342 million...Rybelsus sales increased by 24% measured in Danish kroner and by 26% at CER to DKK 23,301 million...Victoza sales decreased by 37% measured in Danish kroner and by 36% at CER to DKK 5,482 million...Sales of GLP-1 Diabetes care products in the US increased by 24% at CER. The sales increase was mainly driven by continued uptake of Ozempic...Sales of GLP-1 Diabetes care products in EMEA increased by 18% in both Danish kroner and at CER. The sales growth reflects the uptake of Rybelsus and Ozempic, partially offset by lower sales of Victoza...Sales of GLP-1 Diabetes care products in Region China increased by 17% measured in Danish kroner and by 19% at CER. The sales growth mainly reflects the uptake of Ozempic, partially countered by lower sales of Victoza."

Sales • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia. (PubMed, Value Health Reg Issues) - "The results favor the use of analog insulins over human insulins, the former reducing the possibility of acute events and chronic complications to a greater extent."

HEOR • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China. (PubMed, PLoS One) - "Compared with the combined regimen, the use of IDegLira for Chinese patients with type 2 diabetes can improve long-term health output, save medical costs, and is a dominant scheme."

Clinical • HEOR • Journal • Reimbursement • US reimbursement • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Macular Edema • Metabolic Disorders • Myocardial Infarction • Nephrology • Ophthalmology • Pain • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Novo Nordisk A/S | N=266 ➔ 0 | Trial completion date: Sep 2025 ➔ Mar 2026 | Initiation date: May 2024 ➔ Nov 2024 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea (clinicaltrials.gov) - P=N/A | N=750 | Enrolling by invitation | Sponsor: Novo Nordisk A/S | Trial completion date: Jul 2024 ➔ Oct 2024 | Trial primary completion date: Jul 2024 ➔ Oct 2024

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial. (PubMed, Diabetes Obes Metab) - "An intensive remission-induction intervention including fixed-ratio insulin degludec/liraglutide reduced the risk of type 2 diabetes relapse within 1 year without sustained remission."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study. (PubMed, Acta Diabetol) - "In T2D patients with poor metabolic control, either insulin naïve or treated with BOT or MDI, the introduction of IDegLira produces a significant increase in the time spent in good metabolic control and a marked reduction in glycemic fluctuations."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients. (PubMed, Diabetes Metab Syndr Obes) - "Patients were firstly treated with insulin for intensified therapy (Pre-IDegLira group), then switched to insulin degludec and liraglutide (IDegLira) for 3 months (IDegLira-3 months group). IDegLira early conversion demonstrated a positive correlation between fasting blood glucose and HbA1c (r=0.531, p<0.001) or TG level (r=0.336, p=0.002) in T2DM patients. Early conversion of intensive insulin therapy to IDegLira effectively reduced fasting blood glucose and HbA1c in T2DM patients with higher safety."

Journal • Dyslipidemia • Type 2 Diabetes Mellitus

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes (clinicaltrials.gov) - P3 | N=510 | Not yet recruiting | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluating Remission of Type 2 Diabetes Using a Metabolic Intervention Including Fixed-Ratio Insulin Degludec and Liraglutide—A Randomized Controlled Trial (ADA 2024) - "The aim was to evaluate the effect on type 2 diabetes remission of a short-term intensive metabolic intervention consisting of frequent diet, exercise and diabetes management coaching, together with metformin and fixed-ratio insulin degludec/liraglutide. In a multicenter open-label randomized controlled trial, insulin-naïve participants within 5 years of diabetes diagnosis were assigned to a 16-week remission intervention regimen or standard care and were followed for relapse of diabetes and sustained remission for an additional year after stopping glucose-lowering drugs. An intensive remission-induction intervention including fixed-ratio insulin degludec/liraglutide reduced the risk of type 2 diabetes relapse without sustained remission."

Clinical • Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

In-Silico Replay of Insulin Degludec and Liraglutide Clinical Trial Data in Subjects with Type 2 Diabetes (ADA 2024) - P3 | "This work evaluates UVLab's ability to replicate the findings from a 26-week phase 3 clinical trial (NCT01336023) comparing degludec (IDeg), liraglutaide (Lira), and a fixed-ratio combination of the two (IDegLira). IDeg, Lira, and IDegLira were administered to the VS according to clinical trial protocol. UVLab effectively replicates trial outcomes, affirming its predictive capability for T2D treatment. This endorses in-silico models for treatment planning and enhancement of clinical trials."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis. (PubMed, J Evid Based Med) - "In patients with uncontrolled T2DM, the safety and efficacy of FRC and free combination therapy were comparable. The use of FRC is justifiable in patients requiring free combination."

Journal • Retrospective data • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective. (PubMed, J Basic Clin Physiol Pharmacol) - "IcoSema, a groundbreaking approach to diabetes management, combines insulin icodec and semaglutide to offer a transformative treatment option...This comprehensive article evaluates the potential of IcoSema from a clinical pharmacology perspective, examining the pharmacokinetics, efficacy, safety, compliance and cost-effectiveness of its individual components, as well as considering comparable combination therapies like iGlarLixi and IDegLira...Ongoing trials investigating IcoSema are expected to provide valuable insights into its efficacy, safety and comparative effectiveness. By addressing concerns such as potential side effects, individual patient response and drug interactions, healthcare providers can optimize treatment outcomes and enhance the management of type 2 diabetes."

Journal • Review • Diabetes • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd

New P1 trial

The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes (clinicaltrials.gov) - P4 | N=256 | Not yet recruiting | Sponsor: Peking University People's Hospital

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia. (PubMed, Diabetes Ther) - P=N/A | "In real-world practice, initiating IDegLira in patients with T2DM previously treated with basal insulin (± OAD) was associated with improved glycemic control, reduced body weight and reduced risk of hypoglycemia."

Journal • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study. (PubMed, Nutr Metab Cardiovasc Dis) - "Although inertia in insulin initiation and titration was documented in both groups, higher benefit on FBG control was obtained with free vs. fixed combination, likely due to a better titration of BI and GLP-1 RA."

HEOR • Journal • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Long-Term Cost-Effectiveness of iGlarLixi Versus IDegLira in Patients With Uncontrolled Type 2 Diabetes Treated With Basal Insulin or Oral Antidiabetic Drug in China (ISPOR 2024) - "Lifetime simulations demonstrated that iGlarLixi improved clinical outcomes in comparison to IDegLira for Chinese patients with T2D who fail to achieve glycemic targets. Compared to IDegLira, iGlarLixi was dominant in China with higher QALYs and reduced costs."

Clinical • Cost effectiveness • HEOR • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study. (PubMed, Diabetes Ther) - "Our study emphasizes the important role of IDegLira in maintaining a good metabolic control while minimizing the risk of major hypoglycemia and weight gain in the long term. The substantial simplification of treatment schemes can increase adherence."

Journal • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes. (PubMed, Diabetol Int) - "Once-daily IDegLira had greater effects on HbA1c and a lesser increase in insulin doses than IDegAsp when patients are switched from basal insulin therapy. Moreover, the effect on HbA1c was enhanced in patients with high HbA1c levels at baseline."

Journal • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus